NX

Nexentis Technologies Inc.

NXTSBasic MaterialsNASDAQ

Agricultural Inputs

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$0
Net Income
-$4.0M
+22.9% YoY
EBITDA
-$3.4M
+18.7% YoY
Free Cash Flow
-$5.5M

Scan Results

Daily timeframe
DateIndicatorDetails
Aug 19 RSI OverboughtRSI 70.7, above 70, stock may be overbought
Aug 6 MACD Positive CrossoverHistogram +0.0919, positive momentum
About Nexentis Technologies Inc.

Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. With a market capitalization of $2.4M, it sits in micro-cap territory. It operates through two segments, Biotechnology Activity and Renewable Energy Projects.

Where NXTS stands vs its 150-day and 200-day moving averages

As of the August 19, 2026 close, NXTS finished 62.00% below its 150-day moving average ($5.21) and 76.84% below its 200-day moving average ($8.55). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is NXTS overbought or oversold?

At the August 19, 2026 close, NXTS's RSI(14) was 70.7, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$2.4M
P/E (TTM)0.20
EPS$8.25
Beta1.87
52W Change-96.6%
ROE-454.8%
Analysis

Nexentis Technologies Inc. holds $8.9M in cash against $426K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$5.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -454.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $394K (2022) to $0 (2025), a 100% decline worth watching.

With a beta above 1.5, NXTS tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, NXTS has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing NXTS.

Links
More Basic Materials stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms